Publications

2014

Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB. Pharmacological Effects of Two Anti-Methamphetamine Monoclonal Antibodies; Supporting Data for Lead Candidate Selection for Clinical Development. Hum Vaccine Immunother. 2014 10(9): in press.

White SJ, Hendrickson HP, Atchley WT, Laurenzana EM, Gentry WB, Williams DK, Owens SM. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. Drug Metab Dispos. 2014 May 19. pii: dmd.114.056879. PubMed PMID: 24839971

Stevens MW, Tawney RL, West CM, Kight AD, Henry RL, Owens SM, Gentry WB. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. mAbs 2014; 6:547 – 55; PubMed PMID: 24492290; PubMed Central PMCID: PMC3984342.

Peterson EC, Gentry WB, Owens SM. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications. Adv Pharmacol. 2014; 69:107-27. PubMed PMID: 24484976.

2013

Rüedi-Bettschen D, Wood SL, Gunnell MG, West CM, Pidaparthi RR, Carroll FI, Blough BE, Owens SM. Vaccination protects rats from methamphetamine-induced impairment of behavioralresponding for food. Vaccine. 2013 Sep 23;31(41):4596-602. PubMed PMID: 23906885; PubMed Central PMCID: PMC3835592

2011

Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats. Int Immunopharmacol. 2011 Dec;11(12):2181-7. PubMed PMID: 22001428; PubMed Central PMCID: PMC3285273.

Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):892-8. PubMed PMID: 22229314.

Carroll FI, Blough BE, Pidaparthi RR, Abraham P, Gong PK, Deng L, Huang X, Gunnell M, Lay JO Jr, Peterson EC, Owens SM. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem. 2011 Jul 28;54(14):5221-8. PubMed PMID: 21682289; PubMed Central PMCID: PMC3141093.

Hubbard JJ, Laurenzana EM , Williams DK, Gentry WB, Owens SM. The fate and function of therapeutic anti-addiction monoclonal antibodies across the reproductive cycle of rats. J Pharmacol Exp Ther. 2011 Feb;336(2):414-22. PubMed PMID: 20962030; PubMed Central PMCID: PMC3033712.

2010 and previous

Gentry WB, Rüedi-Bettschen D, Owens SM. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther. 2010 Sep;88(3):390-3. PubMed PMID: 20668443.

Carroll FI, Abraham P, Gong PK, Pidaparthi RR, Blough BE, Che Y, Hampton A, Gunnell M, Lay JO Jr, Peterson EC, Owens SM. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem. 2009 Nov 26;52(22):7301-9. PubMed PMID: 19877685; PubMed Central PMCID: PMC2787402.

Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EC, Gentry WB, West M, Che Y, Carroll FI, Owens SM. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine. 2009 Nov 23;27(50):7011-20. PubMed PMID: 19800446; PubMed Central PMCID: PMC2792920.

Peterson EC, Owens SM. Designing immunotherapies to thwart drug abuse. Mol Interv. 2009 Jun;9(3):119-24. PubMed PMID: 19592672; PubMed Central PMCID: PMC2743871.

Gentry WB, Rüedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccin. 2009 Apr;5(4):206-13. PubMed PMID: 19276653; PubMed Central PMCID: PMC2741685.

Lacy HM, Gunnell MG, Laurenzana EM, Owens SM. Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int Immunopharmacol. 2008 Jan;8(1):1-11. PubMed PMID: 18068094; PubMed Central PMCID: PMC2238695.

Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, Liu H, Owens SM. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther. 2007 Jul;322(1):30-9. PubMed PMID: 17452421; PubMed Central PMCID: PMC2764287.

Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol. 2006 Jun;6(6):968-77. PubMed PMID: 16644483.

Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos. 2006 Jun;34(6):906-12. PubMed PMID: 16507651.

Peterson E, Owens SM, Henry RL. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J. 2006 May 26;8(2):E383-90. PubMed PMID: 16796389; PubMed Central PMCID: PMC3231570.

Daniels JR, Wessinger WD, Hardwick WC, Li M, Gunnell MG, Hall CJ, Owens SM, McMillan DE. Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons. Psychopharmacology (Berl). 2006 Mar;185(1):36-44. PubMed PMID: 16479372.

Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol. 2005 Oct 3;521(1-3):86-94. PubMed PMID: 16182279.

McMillan DE, Hardwick WC, Li M, Gunnell MG, Carroll FI, Abraham P, Owens SM. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther. 2004 Jun;309(3):1248-55. PubMed PMID: 14993256.

Laurenzana EM, Byrnes-Blake KA, Milesi-Hallé A, Gentry WB, Williams DK, Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos. 2003 Nov;31(11):1320-6. PubMed PMID: 14570763.

Laurenzana EM, Gunnell MG, Gentry WB, Owens SM. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J Pharmacol Exp Ther. 2003 Sep;306(3):1092-8. PubMed PMID: 12829731.

Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol. 2003 Feb 14;461(2-3):119-28. PubMed PMID: 12586207.

McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav Pharmacol. 2002 Sep;13(5-6):465-73. PubMed PMID: 12394422.

Hardin JS, Wessinger WD, Wenger GR, Proksch JW, Laurenzana EM, Owens SM. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther. 2002 Jul;302(1):119-26. PubMed PMID: 12065708.

Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol. 2001 Feb;1(2):329-38. PubMed PMID: 11360933.

Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther. 2000 Mar;292(3):831-7. PubMed PMID: 10688594.

Proksch JW, Gentry WB, Owens SM. Pharmacokinetic mechanisms for obtaining high renal coelimination of phencyclidine and a monoclonal antiphencyclidine antigen-binding fragment of immunoglobulin G in the rat. J Pharmacol Exp Ther. 1998 Nov;287(2):616-24. PubMed PMID: 9808688.

Lim K, Owens SM, Arnold L, Sacchettini JC, Linthicum DS. Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine. J Biol Chem. 1998 Oct 30;273(44):28576-82. PubMed PMID: 9786848.

Hardin JS, Wessinger WD, Proksch JW, Owens SM. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther. 1998 Jun;285(3):1113-22. PubMed PMID: 9618414.

Owens SM. Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity. NIDA Res Monogr. 1997;173:259-72. PubMed PMID: 9260192.

Valentine JL, Owens SM. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther. 1996 Aug;278(2):717-24. PubMed PMID: 8768723.

Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther. 1996 Aug;278(2):709-16. PubMed PMID: 8768722.

Valentine JL, Arnold LW, Owens SM. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J Pharmacol Exp Ther. 1994 Jun;269(3):1079-85. PubMed PMID: 8014850.

McClurkan MB, Valentine JL, Arnold L, Owens SM. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther. 1993 Sep;266(3):1439-45. PubMed PMID: 8371148.

Egen NB, Bliss M, Mayersohn M, Owens SM, Arnold L, Bier M. Isolation of monoclonal antibodies to phencyclidine from ascites fluid by preparative isoelectric focusing in the Rotofor. Anal Biochem. 1988 Aug 1;172(2):488-94. PubMed PMID: 3189790.

Owens SM, Zorbas M, Lattin DL, Gunnell M, Polk M. Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. J Pharmacol Exp Ther. 1988 Aug;246(2):472-8. PubMed PMID: 2457075.